Weight loss clinics

The company shape

US medical weight loss is a $12 billion to $18 billion category expanding at unprecedented rates driven by GLP-1 receptor agonist medications (semaglutide, tirzepatide, and their branded forms Ozempic, Wegovy, Mounjaro, Zepbound). Category structure was reshaped between 2022 and 2026 as GLP-1 volume moved from endocrinology and obesity medicine into every part of primary care, telehealth platforms, and independent weight loss clinics. Pre-GLP-1 the category revolved around behavior modification, meal replacement, and older pharmacology (phentermine, naltrexone-bupropion). Post-GLP-1 the category revolves around medication access, safety monitoring, and adherence support.

Practice models split into five shapes. The MD or DO-owned medical weight loss clinic with in-person visits, comprehensive metabolic workup, and full-service GLP-1 prescribing at $299 to $650 per month all-in. The NP or PA-led wellness clinic with lighter clinical workup and volume pricing at $199 to $450 per month. The telehealth platform (Ro, Hims, Sesame, Noom Med, Found, Calibrate, WeightWatchers Clinic) at $99 to $349 per month. The compounded semaglutide and tirzepatide clinic operating in the FDA compounding gray zone (largely constrained since October 2024 FDA determination on non-shortage status). The obesity-medicine physician practice (ABOM board-certified) at $400 to $800 per month with premium clinical positioning.

Revenue bands. Solo NP or PA clinic with GLP-1 focus: $250K to $900K in annual revenue with a panel of 100 to 350 active patients. Small group of 2 to 5 clinicians: $1M to $4M. Multi-location or regional group: $4.5M to $22M. National telehealth platform: $50M to $2B+.

Revenue and cost economics shifted meaningfully. Branded GLP-1 medication acquisition cost runs $500 to $1,100 per month at retail without insurance, meaning cash-pay patients face $1,000+ monthly total cost for medication plus clinical fees. Compounded semaglutide and tirzepatide from 503A pharmacies ran $150 to $350 per month during the shortage period but FDA constraints tightened significantly in late 2024 and 2025. Practices that built entire business models on compounded supply face structural risk. Practices that positioned around insurance-covered brand access, comprehensive metabolic care, and post-medication maintenance are the most durable.

Regulatory environment is intense. State medical board scrutiny of GLP-1 prescribing practices (particularly telehealth-only, minimal-workup, high-volume models) is active. FTC scrutiny of weight loss marketing claims is active. FDA scrutiny of compounding pharmacies supplying non-shortage medications is active. Every marketing claim needs compliance review.

Owner economics. A well-run solo NP-led GLP-1 clinic at $700K in revenue nets $200K to $300K to the clinician-owner. A telehealth-focused clinic at $2.5M nets $500K to $900K to owners. National platforms operate on venture-scale unit economics with variable long-term profitability.

The buyer

Medical weight loss buyers cluster into five segments. The insurance-covered GLP-1 patient (typically BMI 30+, or 27+ with comorbidities, employer or plan covers Wegovy or Zepbound with prior authorization, wants a clinic that handles the PA process). The cash-pay branded medication patient (wants brand GLP-1 without insurance coverage or waiting for PA, willing to pay $1,000+ per month). The cash-pay compounded medication patient (was on compounded semaglutide or tirzepatide during shortage era, now facing transition to brand or discontinuation). The comprehensive care patient (wants metabolic workup, dietary support, behavior change coaching, and pharmacotherapy as one program). The post-medication maintenance patient (finished active weight loss, needs support to preserve results and manage weight regain risk).

Insurance-covered patients want a clinic that navigates prior authorization efficiently. PA denial rates for Wegovy and Zepbound run 40 to 65 percent on first submission depending on plan and diagnosis coding. Clinics that specialize in appeals and provide clean documentation win the PA game and hold patients through the appeal cycle.

Cash-pay branded medication patients want speed and access. They Google "Wegovy near me," "how to get Ozempic without insurance," "cheapest way to get GLP-1." They shop on price transparency, appointment availability, and prescriber credentials. Clinics with clear pricing, same-week appointment availability, and honest pharmacy sourcing information convert this segment.

Cash-pay compounded patients are in transition. Many started on $150 to $300 per month compounded semaglutide during the shortage. FDA restrictions have compressed compounding availability, and patients now face transitioning to brand GLP-1 at 3 to 6x the monthly cost or discontinuing. Clinics that offer honest transition counseling (medication tapering, alternative therapies, brand affordability programs, insurance appeals) hold this segment as the market rationalizes.

Comprehensive care patients want more than a prescription. They value metabolic workup (baseline labs, body composition, insulin resistance testing), dietary support (RDN visits, meal planning), muscle preservation coaching (resistance training guidance), and behavior change coaching. Clinics with real multi-disciplinary teams (MD or NP, RDN, exercise physiologist, health coach) capture this premium segment.

Post-medication maintenance patients are the growing subset the category has to serve. GLP-1 discontinuation often produces significant weight regain (roughly two-thirds of lost weight within 12 months for many patients). Clinics with structured maintenance programs (lower-dose maintenance, nutrition, behavior support, other pharmacology options) retain patients well beyond the initial weight loss phase.

Decision drivers across segments: prescriber credentials, medication access options (insurance, cash-pay brand, honest compounding disclosure), price transparency, appointment availability, comprehensive care depth, and reviews with realistic outcome expectations.

HIPAA discipline is heightened because weight loss content combines highly personal health information with photographic before-and-after content. Consent processes need legal review.

Discovery landscape

First-touch attribution for an independent medical weight loss clinic: Google organic 25 to 38 percent (heavy on GLP-1 and weight loss cost queries), Google Business Profile 18 to 26 percent, Google Ads 10 to 18 percent, Instagram and TikTok 8 to 15 percent (largest social contribution of any healthcare category outside nutrition), referral from existing patients 10 to 18 percent, Facebook 4 to 8 percent.

Of the 13 Ranking Surfaces, seven move revenue for medical weight loss. SEO leads because GLP-1 research volume is enormous. LSO for map pack visibility on "weight loss clinic near me" and "Wegovy clinic [city]." E-E-A-T for clinical trust signals in an increasingly regulated category. AEO for GLP-1 and weight loss cost queries. GEO extends AEO. CWV for mobile-first traffic. Content-forward Instagram and TikTok for younger cash-pay demographic.

Instagram and TikTok drive real inbound for weight loss clinics that publish honest, evidence-based content. Clinics with clinician-fronted educational content (side effect management, muscle preservation, protein targeting, plateau management, discontinuation planning) build followings that convert to consultations at reasonable rates. Clinics that publish before-and-after content need explicit consent processes and honest messaging that avoids FTC-flagged claims.

Reddit and Facebook groups (r/Ozempic, r/Semaglutide, r/tirzepatide, Facebook GLP-1 support groups with hundreds of thousands of members) exchange clinic recommendations continuously. Clinics that engage authentically (educational content, honest answers, no cold marketing) receive word-of-mouth referrals at high conversion.

Insurance carrier find-a-provider tools drive volume when clinics are in-network for the dominant commercial carriers. For patients pursuing covered GLP-1, in-network status is decisive. Being in-network compresses per-visit revenue but expands addressable market.

Six surfaces do not move volume meaningfully. VxSO and VSO at low volume. ASO applies only at telehealth platform scale. KGO rare except for named obesity medicine physicians. GLOBO. Web3. AAO is producing measurable answer-engine citation traffic for GLP-1 content; llms.txt v2 and structured content are worth setting up.

What breaks most often

Seven failure modes recur.

Pricing opaque. "Contact us for pricing" pushes prospects to competitors who publish it. Clinics that publish clear monthly pricing (visit fees, medication add-on costs, cash-pay versus insured pathways) convert visitors better. In an increasingly regulated category, hidden pricing raises trust concerns.

Overreaching outcome claims. "Lose 30 pounds in 3 months guaranteed" and similar claims trigger FTC scrutiny under the recent Guides for the Use of Endorsements and Testimonials in Advertising and under weight loss product enforcement history. Realistic outcome ranges with honest caveats ("average patient loses 15 to 20 percent body weight over 12 months on branded semaglutide with dietary support") satisfy compliance and build trust.

Compounded medication marketing without honest supply disclosure. Clinics that continue to market compounded semaglutide or tirzepatide without honest disclosure of FDA constraints since October 2024 face regulatory exposure and patient churn as supply tightens. The fix is honest disclosure and transition planning.

Prior authorization capability invisible. Insurance-covered GLP-1 patients want a clinic that handles PA effectively. Clinics with real PA workflow (dedicated PA staff, appeal templates, denial-rate transparency) capture this segment. Clinics that leave PA to the patient lose the segment to competitors who own the process.

Muscle preservation and comprehensive care missing. Modern GLP-1 clinical understanding recognizes lean mass loss as a significant concern, particularly for older patients. Clinics that fail to address muscle preservation (protein targeting, resistance training coaching, DEXA or InBody monitoring) lose the informed patient segment to more comprehensive programs.

Discontinuation and maintenance planning absent. Clinics that view GLP-1 as a one-way ticket lose patients who face discontinuation decisions (side effects, cost, life changes). Clinics with maintenance protocols, taper planning, and long-term relationship structure retain patients through the full treatment arc.

HIPAA and consent gaps in before-and-after marketing. Weight loss transformation content is high-conversion but high-risk. Clinics that publish before-and-after without proper HIPAA authorization, or that identify patients with linkable details, face breach and reputational exposure. Explicit written consent, retention policies for revoking consent, and legal review of every published transformation are standard.

The Ranking Surfaces Playbook applied

Tier one: revenue this quarter

SEO. Per-medication grid (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, brand-plus-cost combinations). Per-topic grid (GLP-1 side effects, muscle preservation on GLP-1, plateau management, discontinuation and maintenance, insurance coverage, prior authorization). Per-city pages. Consultation-request landing pages. LocalBusiness plus MedicalBusiness plus Physician schema. FAQPage schema.

E-E-A-T. Clinician bios with real credentials (MD, DO, NP, PA, ABOM if applicable, state license, DEA). Practice ownership disclosed. Clinical protocols summarized honestly. FTC-compliant outcome messaging with disclaimers. HIPAA-compliant testimonial process. Named About page.

LSO. GBP rebuild with primary category "Weight loss service" or "Medical clinic" and secondaries for "Endocrinologist" or "Nutritionist" as appropriate. Precise service area. Weekly Posts alternating clinical education, medication updates, patient education, and program spotlights. Systematic HIPAA-aligned review generation.

Tier two: compounds

AEO. Direct-answer guides on 25 to 40 GLP-1 and weight loss cost, insurance, side effect, and discontinuation queries. TL;DR opener, FAQPage schema, honest outcome ranges. Guides bylined by a clinician.

GEO. Organization plus MedicalBusiness schema. sameAs to GBP, state medical board, DEA license, ABOM if applicable, LinkedIn. llms.txt v2 in place because GLP-1 queries land AI-answered at high volume.

CWV. LCP under 2s. Mobile-first for GLP-1 research traffic.

Tier three: social scaling

Instagram and TikTok. Clinician-fronted educational content at 3 to 5 pieces per week. Honest and FTC-compliant. Bio link routes to consultation booking. Engagement with r/Ozempic, r/tirzepatide, and Facebook GLP-1 support groups where authentic and appropriate.

Tier four: not a fit

ASO (unless telehealth platform scale). VxSO, VSO at low volume. KGO rare except for named obesity medicine physicians. GLOBO, Web3. Skip AAO for now, prepare llms.txt v2 as first-mover.

How Playbook priority shifts by clinic size

Solo NP or PA clinic $250K to $900K: SEO plus LSO plus tight site with pricing transparency, clinician bio, PA workflow explained, review generation, top 8 SEO pages on GLP-1 and cost. Small group $1M to $4M: full SEO grid, per-clinician bios, comprehensive care positioning, one social channel, community engagement. Multi-location $4.5M to $22M: full Playbook subset, per-clinic GBP, cross-location content, PA operations at scale, insurance carrier network decisions strategic. Telehealth platform: brand SEO, ASO, national state-license coverage. Regulatory review at every step across all sizes.

First 30 / 60 / 90 days

Days 1 to 30

Attribution baseline. Cost per consult by channel, consult-to-enrollment conversion, retention at month 3 and month 6, and revenue by pathway (insurance, cash-pay brand, compounded transition, comprehensive care). GBP rebuild with correct primary and secondaries. Pricing published clearly with all-in monthly costs by pathway. Insurance and PA workflow explained. Compounding disclosure honest and current with FDA status. FTC-compliant outcome messaging reviewed by counsel. HIPAA-aligned review generation live. Clinician bios with real credentials. Weekly reporting on consults, enrollments, retention curve, and channel mix.

Days 31 to 60

Site restructure. First 12 per-medication and per-topic pages built with clinician bylines and FTC-compliant messaging. Muscle preservation, discontinuation planning, and maintenance protocols surfaced as differentiated content. Before-and-after content with proper HIPAA authorization only. CWV in green. Google Ads restructured into pathway-specific campaigns (insurance PA, cash-pay brand, comprehensive care) with tight negatives. First 8 AEO guides on the highest-intent GLP-1 and cost queries.

Days 61 to 90

Social and community activation. Instagram and TikTok cadence live at 3 to 5 clinician-fronted pieces per week. Authentic engagement with Reddit and Facebook GLP-1 support communities. Referring physician outreach for insurance-covered pathway (primary care, endocrinology). Employer wellness partnership outreach where market supports it. Sixteen AEO guides live cumulative. Rank tracking on medication and cost terms. First map-pack gains and organic ranking gains between day 60 and day 90. Realistic year-one outcomes: 40 to 90 percent consult volume lift, retention at month 6 up 8 to 15 points as comprehensive care differentiates, and revenue mix rebalancing toward durable insurance and comprehensive-care pathways as compounded volume declines.

Measurement stack across the 90-day window

GA4 with events for consult_request, insurance_verify, enrollment_complete, phone_call. CallRail with unique numbers per pathway. Practice management and EHR (Elation, Charm, DrChrono, athenaClinicals) with contact source, pathway, and retention status tagged. Weekly dashboard covering consults by channel, consult-to-enrollment conversion, month 3 and month 6 retention, revenue by pathway, and review count. Cost caps: paid media at 6 to 12 percent of trailing revenue (higher than most healthcare because acquisition remains competitive). SEO and content at 2 to 5 percent. Practice management, review, and compliance software at $500 to $2,500 per month.